Respiratory failure & ventilation
Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial
An erratum to this article was published (JAMA, 28 May 2024 ↗)
Primary result · SupplementalResult — go to the resultBootstrapped adjusted mean difference 5.8 days 95% CI 0.2–11.5- prematurely stopped due to slow enrollment
- Trial prematurely stopped prior to outcome assessment due to slow enrollment
Authors' conclusion
In adult ICU patients with COVID-19 and severe hypoxemia, targeting a Pao2 of 60 mm Hg resulted in more days alive without life support in 90 days than targeting a Pao2 of 90 mm Hg.
Study context
- Population
- Adults with COVID-19 and severe hypoxemia receiving ≥10 L/min oxygen or mechanical ventilation in 11 intensive care unit (ICUs) in Europe, August 2020 to March 2023697 with primary outcome data
- Participants
- 726 adults
- Comparison
- PaO2 target 60 mm Hg vs 90 mm Hg
- Lower oxygenationn = 365
- Higher oxygenationn = 361reference
- Primary endpoint
- Days alive without life support (mechanical ventilation, circulatory support, or kidney replacement therapy)
- Follow-up
- Up to 90 days
Methodological detailsmulticentre
- Multicentre
Primary result
Supplemental
Bootstrapped adjusted mean difference
5.8 days
95% CI 0.2–11.5
P = 0.04
By group
Lower oxygenation vs Higher oxygenation
bootstrapped adjusted mean difference 5.8 days (95% CI 0.2–11.5); P = 0.04
As reported in the abstract
Secondary outcomes
| Outcome | Lower oxygenation | Higher oxygenation | RR (98.6% CI) | P value | |
|---|---|---|---|---|---|
| Mortality · up to 90 days | 30.2% | 34.7% | 0.86 (0.66–1.13) | P = 0.18 | |
| 0.512Relative risk (log scale) |
Days alive and out of hospital · up to 90 days
- No statistically significant difference
Safety
Proportion of patients with serious adverse events · up to 90 days
- No statistically significant difference
Original publication
Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial. JAMA. Published 9 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →